Results 211 to 220 of about 10,004,929 (375)

The Role of Pathology and Oncology in the Anatomic-clinical and Biochemical Particulars of the Oral Tumours [PDF]

, 2001
Victor Vlad Costan, Cristian Constantin Budacu, Vlad Dănilă, Ovidiu Mihail Ștefănescu, Corina Ciupilan, Mihaela Monica Scutariu, Ioan Sârbu, Gabriela Gurău, Victorita Ştefanescu   +8 more
openalex   +1 more source

Endoglin mediates the tumor‐ and metastasis‐promoting traits of stromal myofibroblasts in human breast carcinomas

Molecular Oncology, EarlyView.
Carcinoma‐associated fibroblasts (CAFs) in tumors influence cancer progression. We identified endoglin (ENG) as a key factor in TGF‐β signaling in myofibroblastic CAFs (myCAFs), linked to poor breast cancer outcomes. Inhibiting ENG on myCAFs suppressed the TGF‐β‐Smad2/3 pathway, reducing primary tumor growth and metastasis.
Shoki Okubo, Yoshihiro Mezawa, Zixu Wang, Ahmet Acar, Yasuhiko Ito, Atsushi Takano, Yohei Miyagi, Tomoyuki Yokose, Toshinari Yamashita, Yataro Daigo, Takuya Shirakihara, Akira Orimo   +11 more
wiley   +1 more source

Unveiling the anticancer potential of SGLT-2 inhibitors: mechanisms and prospects in clinical oncology-a narrative review. [PDF]

Eur J Med Res
Li J, Qiao J, Zhang S, Zhong J, Ke C, Lin Y, Li Y, Jin Y, Yao Y, Zhai A, Bi C.   +10 more
europepmc   +1 more source

Delirium in the oncology patient: A clinical dilemma

, 1996
Tracey L. Das Gupta, Petrina N. McGrath
openalex   +2 more sources

Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade

Molecular Oncology, EarlyView.
Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley   +1 more source

Sex and gender differences in cancer research and its application to clinical oncology and therapeutics. [PDF]

Clinics (Sao Paulo)
Lucas-Domínguez R, Rius C, Liu Y, Sixto-Costoya A, Valderrama-Zurián JC.   +4 more
europepmc   +1 more source

Selected topics in clinical oncology [PDF]

, 2001
Susan M. Domchek
openalex   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

US FDA-accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelines. [PDF]

Invest New Drugs
Hakariya H, Ozaki A, Tanimoto T.
europepmc   +1 more source

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

Molecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim, Sungwoo Bae, Jaeyong Choi, Sun‐Wha Im, Bukyoung Cha, Gyeongseo Jung, Sun Wook Cho, Eul‐Ju Seo, Young Ah Lee, Jin Chul Paeng, Young Joo Park, Jong‐Il Kim   +11 more
wiley   +1 more source